Director of Commercial Excellence and Interim Director of Business Unit Cardiology andPulmonology (team of 11)AOP Health, Ismaning/Munich | October 2023 – Present• Leadership & Team Development: Spearheaded the formation and mentorship of a high-performance team, including product managers, sales managers, and key account managers,leading to a 2.6x increase in sales year-over-year.• Strategic Budget Management: Led financial performance reporting and resourceallocation, ensuring alignment with sales goals and strategic objectives.Director of Commercial Excellence (team of 4)AOP Health, Ismaning/Munich | May 2023 – Present• Performance Optimization: Established key performance indicators (KPIs) across allbusiness units, enhancing forecasting accuracy and accelerating sales growth.• Sales Force Effectiveness: Maximized productivity through targeted segmentation andCRM optimization, collaborating closely with management to adapt strategies based onmarket potential and penetration.Head of Marketing October 2019- April 2023Amomed/AOP Health, Ismaning/Munich | October 2019 – April 2023• Omnichannel Marketing: Successfully launched and integrated multiple online and offlineplatforms, driving enhanced customer and patient engagement through cohesive messaging acrossall channels (for example “Forum Medicus” with 3000 annual HCP visits).• Customer-Centric Innovation: Developed strategic product positioning by understanding unmetmarket needs, resulting in increased brand recognition and significant market penetration.• Performance Metrics: Implemented performance indicators that allowed for real-time adjustmentsto marketing strategies based on customer feedback and digital engagement analytics.

Global project lead to assess the potential of new products in development in inflammation/ IBD influenced by Biosimilar affected price erosion &a benefit assessment in several countries: strategic implications for product development (1 Amgen Bravo Awards).Development of a German specific holistic perspective (Medical, Value & Access and Marketing in a team) for various indications to guide product development strategy: relevant and unique insights in Inflammation, CV and Neurology (2 Amgen Bravo Awards).Strategic inputs concerning progression of New Product Development framework model (2 Amgen Bravo Awards).Knowledge transfer & discussion with Senior -European and local -Management concerning new product development status: Quarterly reviews.Matrix cooperation with local established brand functions to share marketing insights and ensure development of common long-term perspective to strengthen customer benefit perception of AMGENs products in Gen Med.

Responsibilities to launch and establish Biosimilars including the first Biosimilar monoclonal antibody in Germany. Lead a team of product manager, marketing assistance etc. Development strategy from marketing perspective in cooperation with commercial team, medical and registration as well as ensuring flawless, successful execution.

Repositioning main products and launch preparation for the first monoclonal antibody biosimilar in Germany.

Revitalized an existing brand through leadership and understanding of the market: As head of the mental health business unit at Schwabe Pharmaceuticals, being responsible for the positive sales development of the third most popular product in the German OTC market (Tebonin®) from a double-digit loss in prior years to an increase in sales of 8% in the first 6 month of 2013.Successful product launch by understanding product strength and customer´s needs: in May 2013 I launched the first product for treating Tinnitus on the German market, with present absolute and relative sales growth surpassing forecasts.Gold award Comprix 2014 for the best advertisement-campaign 2013 in Germany (pharmaceuticals, new advertisements).

Being responsible for strategy development and implementation: 2 x sales increase in a very competitive market - as consequence ABILIFY® became the biggest product for BMS Europe (from 60 million Euros in 2009 to more then130 million Euros in 2012 at the end of the product life-cycle).Development of the first comprehensive digital customer-interaction tool for the European countries: functional leadership/ head of CNS marketing being part of the European marketing innovation team ans working in a matrix function. Creation, development and roll-out of the first comprehensive digital communication campaign (including customer e-mail interaction platform, web-cast and I-Pad use) as first mover in whole Europe.First I-Pad concrete patient digital-aid platform in Europe for sales reps to strengthen customer benefit.

Produktmanager for Risperdal & Consta; launch preparation for of a new indication in Switzerland.Successful repositioning and development of the first digital customer interaction tool in the Swiss market. Repositioning of the most important brand at Janssen-Cilag Switzerland.Sales growth of more than 20% at the end of the product life-cycle.Representation of Switzerland in the global Janssen-Cilag strategy team.

HQ development marketing materials for all countries in the field of Neurology.

Sales & Marketing for Zyprexa, Key-Account Manager, Registration Manager for Europe.As sales rep. award for the strongest relative market share increase (2001-2003).